- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03309605
Phase 1 Study of ELX-02 in Healthy Adult Subjects
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium
- SGS Life Sciences, Clinical Pharmacology Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- Be able and willing to provide written Informed Consent indicating that the subject has been informed of all pertinent aspects of the study.
Healthy female subjects and male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate measurement, 12-lead electrocardiogram (ECG), and clinical laboratory tests.
Female subjects of non-childbearing potential must meet at least one of the following criteria:
- Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; post-menopausal status will be confirmed by a serum follicle-stimulating hormone level;
- Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) will be considered to be of childbearing potential and may be enrolled if they have negative pregnancy tests at screening and admission day and agree to use a highly effective method of contraception for 14 days before first study drug administration and 28 days after last study drug administration. Female subjects of childbearing potential must agree to undergo repeated pregnancy tests.
- Male subjects must be willing to use an effective method of contraception. They must agree to use a condom consistently and correctly, during the course of the study until 28 days after last study drug administration.
- Not using any prescription medication and dietary supplements within 30 days or 5 half lives (whichever is longer) prior to the first study drug administration, except for contraceptives - nor be taking any over-the-counter (OTC) herbal or medicinal products. As an exception, acetaminophen/paracetamol may be used at doses of ≤2 g/day.
- Non-smoking and no use of any tobacco or nicotine products (by declaration) for a period of at least 6 months prior to screening visit.
- Be on no medication with potential to impair renal function (e.g., non steroidal anti inflammatory [NSAID]s) or with ototoxic potential (e.g., quinine, salicylates, aminoglycosides).
- Normal renal function (glomular filtration rate >60 mL/min) based on creatinine plasma concentration and the Modification of Diet in Renal Disease (MDRD) equation for estimated glomular filtration rate. Subjects with lower MDRD clearance can be included on the condition that they have a normal 24h creatinine clearance (determined by a 24h urine collection).
- Negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) serology tests at screening.
- No history of alcohol or DOA. Negative urine test for DOA and alcohol breath test at screening and Day -1.
- No personal history (or current) or hereditary hearing loss, persistent tinnitus, persistent vertigo, persistent imbalance and persistent unsteadiness.
- Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive); and a total body weight >50.0 kg (110 lbs) and <100.0 kg.
Exclusion criteria: Subjects with any of the following characteristics/conditions will not be included in the study:
- Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are the Sponsor employees directly involved in the conduct of the study.
- Concurrent participation or participation in another clinical trial within at least 5 tissue half-lives prior to dosing (calculated from the previous study's last dosing day). If the previous trial involved agents with delayed effects or prolonged metabolism, a 12 months interval is required.
- Evidence or history of clinically relevant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies). This includes any acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
- Presence of mitochondrial mutations making subject susceptible to aminoglycoside toxicity.
- Subjects with any history of ear disease or surgeries, persistent dizziness or persistent tinnitus.
Subjects with any abnormality at screening, that indicates the presence of a vestibular pathology, conductive hearing loss or balance problem (by an ENT).
Subjects with abnormalities in audiometry results at screening as follows: any pure-tone threshold >55 dB and/or inter-ear difference in any frequency of >20 dB.
Dizziness Handicap Inventory (DHI)-H score>16. Tinnitus Handicap Inventory (THI)-H score >14.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening.
- Screening supine BP ≥ 140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic), following at least 5 min of supine rest. If BP is ≥ 140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
- Screening supine 12-lead ECG demonstrating QTc >450 msec for men and >470 msec for women, or a QRS interval >120 msec. If QTc or QRS exceed these limits, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
- Subjects with ANY abnormalities in clinical laboratory tests at screening, considered by the study physician as clinically relevant. In particular, subjects with alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine and total bilirubin ≥ 1.5 upper limit of normal will be excluded.
- Pregnant or breastfeeding female subjects.
- Subjects who donated blood or received blood or plasma derivatives in the three months preceding study drug administration.
- Unwilling or unable to comply with all scheduled visits, treatment plan, laboratory tests and other study procedures and the restrictions described in this protocol.
- Known relevant allergy to any drug and/or aminoglycosides.
- Subjects with an inability to communicate well with the Investigators and CPU staff (e.g., language problem, poor mental development).
- Subjects with visual impairment or inability to read and comprehend the DHI and THI scales.
- Subjects with any acute medical situation (e.g., acute infection) within 48 hours of study start, which is considered of significance by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Comparator Arm
Placebo
|
Placebo
|
Experimental: ELX-02
|
ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Parameters - Plasma AUC0-24
Time Frame: Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose
|
Day 1 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 to 24 hours post-ose
|
Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose
|
Pharmacokinetic Parameters- Plasma AUC0-24
Time Frame: Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose
|
Day 29 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 to 24 hours post-dose
|
Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose
|
Pharmacokinetic Parameters - Plasma Cmax
Time Frame: Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h, post-dose
|
Day 1 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 1 to 72 hours post-dose
|
Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h, post-dose
|
Pharmacokinetic Parameters - Plasma Cmax
Time Frame: Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose
|
Day 29 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 29 to 72 hours post-dose
|
Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose
|
Pharmacokinetic Parameter - Plasma AUC0-inf
Time Frame: Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose
|
Day 1 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 extrapolated to infinity
|
Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose
|
Pharmacokinetic Parameter - Plasma AUC0-inf
Time Frame: Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose
|
Day 29 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 extrapolated to infinity
|
Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose
|
Pharmacokinetic Parameter - Plasma Tmax
Time Frame: Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose
|
Day 1 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 1
|
Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose
|
Pharmacokinetic Parameter Plasma - Tmax
Time Frame: Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose
|
Day 29 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 29
|
Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose
|
Pharmacokinetic Parameter - Plasma Rac(AUC24h)
Time Frame: Day 1 and Day 24 hr
|
Accumulation ratio, calculated as AUC24h Day29/AUC24h Day 1
|
Day 1 and Day 24 hr
|
Pharmacokinetic Parameter - Plasma RAC(Cmax)
Time Frame: Day 1 and Day 29
|
Accumulation ratio, calculated as Cmax Day29/Cmax Day 1
|
Day 1 and Day 29
|
Urine Pharmacokinetics Parameter - Ae72h
Time Frame: Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Day 1 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 1
|
Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Urine Pharmacokinetics Parameter - Ae72h
Time Frame: Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Day 29 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 29
|
Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Urine Pharmacokinetic Parameter - Rmax
Time Frame: Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Day 1 Maximum rate of urinary extraction (Rmax) of EXL-02 in each collection time interval following the subcutaneous (SC) dose on Day 1
|
Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Urine Pharmacokinetic Parameter - Rmax
Time Frame: Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Day 29 Maximum rate of urinary extraction (Rmax) of ELX-02 in each collection time interval following the subcutaneous (SC) dose on Day 29
|
Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose
|
Urine Pharmacokinetics Parameter - Fe12h Day 1
Time Frame: 12 hours
|
Percent of dose excreted (Fe) in urine on Day 1
|
12 hours
|
Urine Pharmacokinetics Parameter - Fe 12h on Day 29
Time Frame: 12 h on Day 29
|
Percent of dose excreted (Fe) in urine on Day 29
|
12 h on Day 29
|
Urine Pharmacokinetics Parameter - CLR24h on Day 1
Time Frame: 24 hours
|
Renal clearance on Day 1 (CLR=Ae24h/plasmaAUC24h)
|
24 hours
|
Urine Pharmacokinetics Parameter - CLR24h
Time Frame: 24 h
|
Renal clearance on Day 29 (CLR=Ae24h/plasmaAUC24h)
|
24 h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Day 1-29
|
TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment
|
Day 1-29
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EL-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Disease
-
Boston Children's HospitalNational Human Genome Research Institute (NHGRI)Active, not recruitingGenetic Disease | Genetic PredispositionUnited States
-
Boston Children's HospitalRecruitingGenetic Predisposition to Disease | Genetic Disease | Development, Infant | Genetic Syndrome | Development, ChildUnited States
-
National Cancer Institute (NCI)Active, not recruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
University of WashingtonNational Cancer Institute (NCI)Completed
-
Anahuac UniversityCompletedGenetic Predisposition | Carrier, GestationalMexico
-
University Hospital TuebingenCharite University, Berlin, Germany; RWTH Aachen University; Medical University...Not yet recruiting
-
King Hussein Cancer CenterActive, not recruiting
-
University of Texas Southwestern Medical CenterNational Society of Genetic CounselorsCompletedGenetic PredispositionUnited States
-
National Cancer Institute (NCI)RecruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
St. Jude Children's Research HospitalRecruitingGenetic PredispositionUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States